Neuronal Ceroid Lipofuscinosis: Potential for Targeted Therapy
- PMID: 33242182
- DOI: 10.1007/s40265-020-01440-7
Neuronal Ceroid Lipofuscinosis: Potential for Targeted Therapy
Abstract
Neuronal ceroid lipofuscinosis (NCLs) is a group of inherited neurodegenerative lysosomal storage diseases that together represent the most common cause of dementia in children. Phenotypically, patients have visual impairment, cognitive and motor decline, epilepsy, and premature death. A primary challenge is to halt and/or reverse these diseases, towards which developments in potential effective therapies are encouraging. Many treatments, including enzyme replacement therapy (for CLN1 and CLN2 diseases), stem-cell therapy (for CLN1, CLN2, and CLN8 diseases), gene therapy vector (for CLN1, CLN2, CLN3, CLN5, CLN6, CLN7, CLN10, and CLN11 diseases), and pharmacological drugs (for CLN1, CLN2, CLN3, and CLN6 diseases) have been evaluated for safety and efficacy in pre-clinical and clinical studies. Currently, cerliponase alpha for CLN2 disease is the only approved therapy for NCL. Lacking is any study of potential treatments for CLN4, CLN9, CLN12, CLN13 or CLN14 diseases. This review provides an overview of genetics for each CLN disease, and we discuss the current understanding from pre-clinical and clinical study of potential therapeutics. Various therapeutic interventions have been studied in many experimental animal models. Combination of treatments may be useful to slow or even halt disease progression; however, few therapies are unlikely to even partially reverse the disease and a complete reversal is currently improbable. Early diagnosis to allow initiation of therapy, when indicated, during asymptomatic stages is more important than ever.
Similar articles
-
The Neuronal Ceroid Lipofuscinoses.In: Noebels JL, Avoli M, Rogawski MA, Vezzani A, Delgado-Escueta AV, editors. Jasper's Basic Mechanisms of the Epilepsies. 5th edition. New York: Oxford University Press; 2024. Chapter 50. In: Noebels JL, Avoli M, Rogawski MA, Vezzani A, Delgado-Escueta AV, editors. Jasper's Basic Mechanisms of the Epilepsies. 5th edition. New York: Oxford University Press; 2024. Chapter 50. PMID: 39637217 Free Books & Documents. Review.
-
Genetics of the neuronal ceroid lipofuscinoses (Batten disease).Biochim Biophys Acta. 2015 Oct;1852(10 Pt B):2237-41. doi: 10.1016/j.bbadis.2015.05.011. Epub 2015 May 27. Biochim Biophys Acta. 2015. PMID: 26026925 Free PMC article. Review.
-
Cell biology of the NCL proteins: What they do and don't do.Biochim Biophys Acta. 2015 Oct;1852(10 Pt B):2242-55. doi: 10.1016/j.bbadis.2015.04.027. Epub 2015 May 8. Biochim Biophys Acta. 2015. PMID: 25962910 Review.
-
Therapeutic approaches to the challenge of neuronal ceroid lipofuscinoses.Curr Pharm Biotechnol. 2011 Jun;12(6):867-83. doi: 10.2174/138920111795542633. Curr Pharm Biotechnol. 2011. PMID: 21235444 Free PMC article. Review.
-
Advances in the Treatment of Neuronal Ceroid Lipofuscinosis.Expert Opin Orphan Drugs. 2019;7(11):473-500. doi: 10.1080/21678707.2019.1684258. Epub 2019 Nov 27. Expert Opin Orphan Drugs. 2019. PMID: 33365208 Free PMC article.
Cited by
-
Abnormal triaging of misfolded proteins by adult neuronal ceroid lipofuscinosis-associated DNAJC5/CSPα mutants causes lipofuscin accumulation.Autophagy. 2023 Jan;19(1):204-223. doi: 10.1080/15548627.2022.2065618. Epub 2022 May 4. Autophagy. 2023. PMID: 35506243 Free PMC article.
-
Experimental Therapeutic Approaches for the Treatment of Retinal Pathology in Neuronal Ceroid Lipofuscinoses.Front Neurol. 2022 Apr 18;13:866983. doi: 10.3389/fneur.2022.866983. eCollection 2022. Front Neurol. 2022. PMID: 35509995 Free PMC article. Review.
-
Early recognition of CLN3 disease facilitated by visual electrophysiology and multimodal imaging.Doc Ophthalmol. 2023 Jun;146(3):241-256. doi: 10.1007/s10633-023-09930-1. Epub 2023 Mar 25. Doc Ophthalmol. 2023. PMID: 36964447 Free PMC article.
-
Two compound heterozygous variants in the CLN8 gene are responsible for neuronal cereidolipofuscinoses disorder in a child: a case report.Front Pediatr. 2024 May 1;12:1379254. doi: 10.3389/fped.2024.1379254. eCollection 2024. Front Pediatr. 2024. PMID: 38751748 Free PMC article.
-
Defective anterograde protein-trafficking contributes to endoplasmic reticulum-stress in a CLN1 disease model.Neurobiol Dis. 2025 Jun 1;209:106890. doi: 10.1016/j.nbd.2025.106890. Epub 2025 Mar 28. Neurobiol Dis. 2025. PMID: 40158736
References
-
- Donsante A, Boulis NM. Progress in gene and cell therapies for the neuronal ceroid lipofuscinoses. Expert Opin Biol Ther. 2018;18:755–64. https://doi.org/10.1080/14712598.2018.1492544 . - DOI - PubMed
-
- Johnson TB, Cain JT, White KA, Ramirez-Montealegre D, Pearce DA, Weimer JM. Therapeutic landscape for Batten disease: current treatments and future prospects. Nat Rev Neurol. 2019;15:161–78. https://doi.org/10.1038/s41582-019-0138-8 . - DOI - PubMed - PMC
-
- Kohlschütter A, Schulz A, Bartsch U, Storch S. Current and Emerging Treatment Strategies for Neuronal Ceroid Lipofuscinoses. CNS Drugs. 2019;33:315–25. https://doi.org/10.1007/s40263-019-00620-8 . - DOI - PubMed - PMC
-
- Platt FM. Emptying the stores: lysosomal diseases and therapeutic strategies. Nat Rev Drug Discov. 2018;17:133–50. http://www.nature.com/articles/nrd.2017.214
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous